QURE: Rounding Bottom detected on 19 Aug 2026

QURE is forming a rounding bottom pattern following a wider net loss of $81.06M in Q2 2026, with the stock now at $47.38—442.73% above its 52-week low but 33.73% below its 52-week high. The pattern exhibits solid structure (13/15), acceptable volume (11/12), and breakout quality (11/13) yielding an overall score of 71, with a 64.72% win probability. Key support sits at $8.73, resistance at $27.51. The measured move target of $49.43 suggests a modest 4.3% breakout, while rising momentum indicators (RSI 63.43, MACD histogram positive, Bollinger Band position 0.775) and positive 3-month gains of 90.05% indicate strength. Volume remains subdued (0.36x normal), a caution flag for confirmation.

uniQure is on track to submit a BLA for AMT-130 in Q3 2026, a milestone reflecting years of gene therapy development for Huntington's disease. Positive 36-month high-dose data for AMT-130 showed significant slowing of Huntington's disease progression, supporting plans for a BLA submission. The FDA now accepts Phase 1/2 data for AMT-130 as the primary basis for accelerated approval, with QURE planning a BLA submission in Q3 2026 and potential US market launch before year-end if granted priority review. The company has expanded headcount and invested in commercial readiness for a potential AMT-130 launch; cash runway is projected into 2030. Despite accelerating late-stage pipeline progress, the company reported widening losses and low quarterly revenue ($5.84M), creating a fundamental disconnect between near-term cash burn and catalytic potential.

A successful breakout above resistance at $27.51 would target $49.43 conservatively, representing a contained 4.3% move—unusually tight for a rounding bottom, suggesting the pattern may be in early formation. Historical data indicates 64.72% win probability for this setup. Volume confirmation is critical: the current 0.36x relative volume is well below the 1.0x+ needed for conviction. The invalidation level sits at $8.73 support; a close below that price would negate the pattern and signal continuation of prior downtrends. Watch for volume acceleration on breakout attempts; without it, breakout conviction remains questionable despite bullish technicals.

The widening net loss of $81.06M versus $37.72M year-over-year represents deteriorating profitability trends, with diluted EPS worsening to negative $1.22. Clinical execution and regulatory approval risk remains substantial—gene therapy programs are capital-intensive and face uncertain FDA pathways despite recent progress. Four-year clinical data for AMT-130 is due in September 2026, creating near-term event risk; negative long-term safety or efficacy data could crush the stock. Volume ratio of 0.36x signals weak participation; institutional buying may not be confirmed. Biotechnology sector volatility remains elevated (20-day volatility 50.46%), though beta of 0.52 provides some downside cushion relative to the market. The stock has rallied 90% in three months; profit-taking risk is elevated ahead of Q3 BLA submission.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.